PharmaSecure launches second phase of TB control program in India
The program, which receives funding from the USAID and The Gates Foundation, is designed to discover innovative solutions to raise the health outcomes of patients who have tuberculosis (TB).
The results taken from the program’s first phase prove that patients involved in the company’s psConnect patient management platform were 60 percent more likely to report that they had adhered to the drug regiment to treat TB. This is a significant increase compared to patients who are not enrolled in the program.
For the first phase of the program, PharmaSecure used personalized incentives and reminders to help patients with TB to finish their TB treatment regimen. These reminders and incentives kept the patients engaged as well as managed their adherence to the drugs.
PharmaSecure is just one of four organizations that was nominated to launch the second phase of the program. The goal is to transform the delivery of healthcare in emerging markets by thoroughly tracking and monitor the distribution practices of medicines. Analysts then use the data to better understand the outcomes and behaviors of the patients who receive the medications.